Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Last verified 25 Sep 2026 · Editorial standards

At a glance

Pembrolizumab is named as an intervention in 409 current clinical trials in our USA, China, UK, Ireland and India registers. 232 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Merck Sharp & Dohme LLC (68). The most-studied condition is Non-small Cell Lung Cancer.

Pembrolizumab also has an approved-drug profile on this site (FDA label data): Keytruda (Pembrolizumab) →

Trials by status

Recruiting23257%
Not yet open133%
Active, closed16139%
By invitation31%

Trials by phase

Phase 311729%
Phase 1/210225%
Phase 18521%
Phase 28220%
Phase 2/3174%
Observational31%
Phase EARLY_PHASE110%
Not applicable10%
Phase 410%

Clinical trials of Pembrolizumab

409 trials

Study	Phase	Status	Lead sponsor	Registers
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) NCT03486873 · Solid Tumors, Hematologic Malignancies	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) NCT04807673 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors NCT05055908 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 3	Recruiting	Hunan Province Tumor Hospital	China
Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets NCT05317858 · ClinicalTrials.gov ↗ · Brain Tumor, Non Small Cell Lung Cancer	Phase 3	Recruiting	InSightec	USA
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) NCT05633654 · Triple Negative Breast Cancer	Phase 3	Recruiting	Gilead Sciences	Ireland, UK, USA
Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904 · ClinicalTrials.gov ↗ · Metastatic Melanoma, Unresectable Melanoma, Melanoma	Phase 3	Recruiting	Iovance Biotherapeutics, Inc.	UK, USA
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients NCT05899608 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Summit Therapeutics	Ireland, UK, USA, China
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) NCT05920356 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	Amgen	UK, USA, China
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC NCT06102395 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab	Phase 3	Recruiting	Beijing Tongren Hospital	China
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) NCT06103864 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer NCT06119581 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis	Phase 3	Recruiting	Eli Lilly and Company	UK, USA, India, China
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) NCT06170788 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC NCT06216301 · Metastatic Non-small Cell Lung Cancer	Phase 3	Recruiting	NovoCure GmbH	UK, USA
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] NCT06264180 · ClinicalTrials.gov ↗ · Advanced Melanoma	Phase 3	Recruiting	Replimune, Inc.	UK, USA
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer NCT06282575 · ClinicalTrials.gov ↗ · Biliary Tract Cancer	Phase 3	Recruiting	Jazz Pharmaceuticals	UK, USA, India, China
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176 · Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) NCT06345729 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations NCT06357533 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] NCT06422143 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, NSCLC	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) NCT06452277 · Advanced Non-small Cell Lung Cancer, HER2 Mutation	Phase 3	Recruiting	Bayer	UK, USA, China
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) NCT06525220 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Merus B.V.	UK, USA
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer NCT06532006 · ClinicalTrials.gov ↗ · Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer	Phase 3	Recruiting	Shanghai Henlius Biotech	USA, China
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer NCT06545955 · Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	Phase 3	Recruiting	Ferring Pharmaceuticals	USA
EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma NCT06556563 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 3	Recruiting	NovoCure GmbH	UK, USA
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% NCT06561386 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, India, China
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Non-Squamous NSCLC NCT06627647 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc.	USA, China
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer NCT06731478 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, China
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126 · ClinicalTrials.gov ↗ · Melanoma, Cutaneous Malignant	Phase 3	Recruiting	Immatics US, Inc.	UK, USA
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC NCT06754644 · ClinicalTrials.gov ↗ · NSCLC	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd.	China
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. NCT06758401 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)	Phase 3	Recruiting	Pfizer	UK, USA, India, China
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer NCT06764875 · ClinicalTrials.gov ↗ · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 NCT06767514 · Non-Small Cell Lung Cancer	Phase 3	Recruiting	Summit Therapeutics	USA, China
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06793215 · Non-Small Cell Lung Cancer, KRAS G12C Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	Ireland, UK, USA, China
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer NCT06868277 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small Cell Lung	Phase 3	Recruiting	AstraZeneca	Ireland, UK, USA, China
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) NCT06875310 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Mirati Therapeutics Inc.	Ireland, UK, USA, India, China
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer NCT06890598 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Eli Lilly and Company	UK, USA, India, China
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer NCT06899126 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, India, China
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer NCT06901531 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	UK, USA, China
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · ClinicalTrials.gov ↗ · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China
SSGJ-707 in Advanced Non-Small Cell Lung Cancer NCT06980272 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer	Phase 3	Recruiting	Shenyang Sunshine Pharmaceutical Co., LTD.	China
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · ClinicalTrials.gov ↗ · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC NCT07178795 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) NCT07190248 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations NCT07195695 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract NCT07218380 · ClinicalTrials.gov ↗ · Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Neoplasm Metastasis	Phase 3	Recruiting	Eli Lilly and Company	UK, USA, China
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07222566 · ClinicalTrials.gov ↗ · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Pfizer	USA, India, China
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer NCT07276399 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 3	Recruiting	Janssen Research & Development, LLC	UK, USA, India, China
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. NCT07315750 · ClinicalTrials.gov ↗ · Gastric Carcinoma	Phase 3	Recruiting	RemeGen Co., Ltd.	China
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) NCT07361510 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) NCT07541170 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Recruiting	Hoffmann-La Roche	USA
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309) NCT07566156 · ClinicalTrials.gov ↗ · Urothelial Cancer, Urinary Bladder Neoplasms	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	USA
Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) NCT07660094 · ClinicalTrials.gov ↗ · Non-squamous, Non-Small Cell Lung Cancer	Phase 3	Recruiting	Candel Therapeutics, Inc.	USA
A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer NCT07673887 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 3	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer NCT07679360 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd.	China
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC NCT07720284 · High-risk Muscle Invasive Urothelial Carcinoma	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease NCT07750158 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 3	Recruiting	Exelixis	USA
Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC NCT07777822 · ClinicalTrials.gov ↗ · NSCLC, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer NSCLC	Phase 3	Recruiting	Revolution Medicines, Inc.	USA
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 NCT04613596 · Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	Mirati Therapeutics Inc.	Ireland, UK, USA, India, China
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) NCT06236438 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2/3	Recruiting	AbbVie	USA
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552 · Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma	Phase 2/3	Recruiting	Vasgene Therapeutics, Inc	USA
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma NCT06624644 · Melanoma (Skin Cancer), Melanoma Stage IIIB-IV, Cutaneous Melanoma	Phase 2/3	Recruiting	Linnaeus Therapeutics, Inc.	USA
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. NCT06697301 · ClinicalTrials.gov ↗ · Advanced Melanoma	Phase 2/3	Recruiting	Eikon Therapeutics	UK, USA
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer NCT06712316 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2/3	Recruiting	BioNTech SE	UK, USA, China
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC NCT06788990 · ClinicalTrials.gov ↗ · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 2/3	Recruiting	Bicara Therapeutics	Ireland, UK, USA, India
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma NCT06947928 · Advanced Or Metastatic Merkel Cell Carcinoma	Phase 2/3	Recruiting	TuHURA Biosciences, Inc.	USA
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion NCT07063745 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer With MTAP Deletion	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. NCT07365319 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC	Phase 2/3	Recruiting	Eikon Therapeutics	USA
A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma NCT07815665 · ClinicalTrials.gov ↗ · Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC)	Phase 2/3	Recruiting	Summit Therapeutics	USA
Pan Tumor Rollover Study NCT03899155 · Cancer	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, UK, USA, China
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in China NCT04857164 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Yuankai Shi	China
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 NCT04879329 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 2	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT04920617 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma	Phase 2	Recruiting	ImmunoVaccine Technologies, Inc. (IMV Inc.)	USA
Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846 · ClinicalTrials.gov ↗ · ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer NCT05284539 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial NCT05327686 · ClinicalTrials.gov ↗ · Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8	Phase 2	Recruiting	NRG Oncology	Ireland
4 Courses vs 2 Courses of Pembrolizumab Combined With Carboplatin and Albumin-binding Paclitaxel of Neoadjuvant Therapy in HNSCC NCT05980702 · ClinicalTrials.gov ↗ · HNSCC, Oral Cancer, PD-1	Phase 2	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Efficacy and Safety of PD-1 Plus Chemotherapy in Poorly Differentiated Locally Advanced (LA) HNSCC NCT06100497 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Beijing Tongren Hospital	China
PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer NCT06157151 · ClinicalTrials.gov ↗ · Cervical Cancer, HPV-Related Carcinoma, HPV-Related Malignancy	Phase 2	Recruiting	Precigen, Inc	USA
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients NCT06284590 · ClinicalTrials.gov ↗ · Melanoma Stage III, Melanoma Stage IV	Phase 2	Recruiting	Philogen S.p.A.	USA
ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI NCT06388031 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Peking Union Medical College Hospital	China
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis NCT06389422 · ClinicalTrials.gov ↗ · Hepatocellular Carcinoma, Radiotherapy, Pembrolizumab	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Checkpoint Inhibitor Combinations Therapy as First Line for HCC Via IT NCT06482801 · ClinicalTrials.gov ↗ · Liver Cancer, Antibody	Phase 2	Recruiting	Second Affiliated Hospital of Guangzhou Medical University	China
Checkpoint Inhibitor Combinations Therapy as First Line for Inoperable Lung Cancer Via IT NCT06483347 · ClinicalTrials.gov ↗ · Lung Cancer, Inoperable Disease	Phase 2	Recruiting	Second Affiliated Hospital of Guangzhou Medical University	China
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer NCT06708858 · ClinicalTrials.gov ↗ · Advanced Biliary Tract Cancer	Phase 2	Recruiting	Dai, Guanghai	China
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy NCT06797297 · ClinicalTrials.gov ↗ · Melanoma	Phase 2	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	China
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · ClinicalTrials.gov ↗ · Breast Neoplasms, Breast Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
Probiotics in Advanced Urothelial Carcinoma NCT06904573 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma, Probiotics, Immunotherapy	Phase 2	Recruiting	Sun Yat-sen University	China
A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) NCT06961006 · ClinicalTrials.gov ↗ · Malignant Melanoma	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA
A Study of BL-B01D1+TKI±Pembrolizumab in Patients With Locally Advanced or Metastatic Renal Cancer NCT06962787 · ClinicalTrials.gov ↗ · Renal Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC NCT07098988 · ClinicalTrials.gov ↗ · Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor	Phase 2	Recruiting	CatalYm GmbH	USA
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer NCT07122687 · ClinicalTrials.gov ↗ · Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	Phase 2	Recruiting	Innovent Biologics (Suzhou) Co. Ltd.	China
ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC NCT07157969 · ClinicalTrials.gov ↗ · HCC - Hepatocellular Carcinoma	Phase 2	Recruiting	Peking Union Medical College Hospital	China
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) NCT07221474 · Squamous Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) NCT07252739 · Malignant Neoplasm	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC NCT07264816 · ClinicalTrials.gov ↗ · Non-squamous Non-small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	China
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 2	Recruiting	Mirati Therapeutics Inc.	UK, USA, China
ILKN421H Plus Pembrolizumab in Advanced Non-Small Cell Lung Cancer NCT07452224 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	iLeukon Therapeutics, Inc.	USA
A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder NCT07475806 · ClinicalTrials.gov ↗ · Muscle-invasive Bladder Cancer	Phase 2	Recruiting	Astellas Pharma Global Development, Inc.	UK, USA
Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab NCT07486817 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell	Phase 2	Recruiting	Boehringer Ingelheim	China
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) NCT07622186 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
A Phase II Study to Evaluate the Efficacy and Safety of SKB571 in Recurrent or Metastatic HNSCC Participants NCT07668154 · ClinicalTrials.gov ↗ · HNSCC	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC NCT07807163 · ClinicalTrials.gov ↗ · Metastatic Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Bicara Therapeutics	USA
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum NCT07811193 · ClinicalTrials.gov ↗ · Colorectal Adenocarcinoma	Phase 2	Recruiting	Vividion Therapeutics, Inc.	UK, USA, China
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) NCT02332668 · Melanoma, Lymphoma, Solid Tumor	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) NCT04165070 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Inhibrx Biosciences, Inc	USA
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer	Phase 1/2	Recruiting	PMV Pharmaceuticals, Inc	UK, USA
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 NCT04787042 · Cancer, Solid Tumor, Melanoma	Phase 1/2	Recruiting	Simcha IL-18, Inc.	USA
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer	Phase 1/2	Recruiting	GI Innovation, Inc.	USA
A Beta-only IL-2 ImmunoTherapY Study NCT05086692 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma	Phase 1/2	Recruiting	Medicenna Therapeutics, Inc.	Ireland, USA
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors NCT05101070 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1/2	Recruiting	Shionogi	USA
First in Human Study of T3P-Y058-739 (T3P) NCT05120596 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	T3 Pharmaceuticals AG	UK
RAPA-201 Therapy of Solid Tumors NCT05144698 · ClinicalTrials.gov ↗ · Solid Tumor, Small Cell and Non-small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Rapa Therapeutics LLC	USA
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors NCT05187338 · ClinicalTrials.gov ↗ · Lung Cancer, Liver Cancer, Colorectal Cancer	Phase 1/2	Recruiting	Second Affiliated Hospital of Guangzhou Medical University	China
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study in Patients With Advanced Cancers NCT05320588 · ClinicalTrials.gov ↗ · Advanced Cancer, Advanced Solid Tumor, Cancer	Phase 1/2	Recruiting	BiOneCure Therapeutics Inc.	USA
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer NCT05329532 · Triple Negative Breast Cancer, Renal Cell Cancer, High Grade Ovarian Serous Adenocarcinoma	Phase 1/2	Recruiting	Scancell Ltd	UK
To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers NCT05356741 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic HER2-Expressing Cancers	Phase 1/2	Recruiting	Vir Biotechnology, Inc.	USA
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors NCT05394103 · ClinicalTrials.gov ↗ · Advanced Cancer, Metastatic Cancer	Phase 1/2	Recruiting	Qurient Co., Ltd.	USA
ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors NCT05405595 · ClinicalTrials.gov ↗ · Advanced/Metastatic Solid Tumors	Phase 1/2	Recruiting	Adagene Inc	USA, China
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation NCT05410145 · ClinicalTrials.gov ↗ · KRAS P.G12C	Phase 1/2	Recruiting	D3 Bio (Wuxi) Co., Ltd	USA, China
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) NCT05431270 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma	Phase 1/2	Recruiting	Phanes Therapeutics	USA
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma NCT05440708 · Hepatocellular Carcinoma	Phase 1/2	Recruiting	Tvardi Therapeutics, Incorporated	USA
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors NCT05533697 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	ModernaTX, Inc.	UK, USA
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A) NCT05562830 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366 · ClinicalTrials.gov ↗ · High Grade Epithelial Ovarian Cancer, High Grade Serous Ovarian Cancer, Primary Peritoneal Carcinoma	Phase 1/2	Recruiting	Genmab	USA, China
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies NCT05669430 · Solid Tumor, Adult, Refractory Cancer, Endometrial Carcinoma (EC)	Phase 1/2	Recruiting	GV20 Therapeutics	USA
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors NCT05732831 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumor	Phase 1/2	Recruiting	Tango Therapeutics, Inc.	USA
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 NCT05761223 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	1ST Biotherapeutics, Inc.	USA
Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors NCT05784688 · Solid Tumor, Biliary Tract Cancer, Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	TiumBio Co., Ltd.	USA
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation NCT05789082 · Non-Small Cell Lung Cancer	Phase 1/2	Recruiting	Hoffmann-La Roche	UK, USA, China
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors NCT05797168 · ClinicalTrials.gov ↗ · Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) NCT05824975 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)	Phase 1/2	Recruiting	GI Innovation, Inc.	USA
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer NCT05877430 · NSCLC, HNSCC, Melanoma	Phase 1/2	Recruiting	CJ Bioscience, Inc.	USA
LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer NCT05886439 · ClinicalTrials.gov ↗ · Lung Cancer	Phase 1/2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors NCT05970497 · Cancer, Melanoma Stage III, Melanoma Stage IV	Phase 1/2	Recruiting	Krystal Biotech, Inc.	USA
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients With Head-Neck Squamous Cell Carcinoma NCT06016920 · ClinicalTrials.gov ↗ · HPV Positive Oropharyngeal Squamous Cell Carcinoma, HNSCC	Phase 1/2	Recruiting	Nykode Therapeutics ASA	UK
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc.	USA
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies. NCT06137144 · ClinicalTrials.gov ↗ · Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma	Phase 1/2	Recruiting	AstraZeneca	UK, USA, China
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC NCT06162221 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer	Phase 1/2	Recruiting	Revolution Medicines, Inc.	USA
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs NCT06228326 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult	Phase 1/2	Recruiting	Krystal Biotech, Inc.	USA
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer NCT06385080 · ClinicalTrials.gov ↗ · Squamous Cell Carcinoma of Head and Neck	Phase 1/2	Recruiting	Janssen Research & Development, LLC	UK, USA, China
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) NCT06428409 · Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) NCT06469944 · ClinicalTrials.gov ↗ · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer NCT06530303 · ClinicalTrials.gov ↗ · Colorectal Cancer, Colon Cancer, Rectum Cancer	Phase 1/2	Recruiting	Essen Biotech	China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer NCT06532799 · ClinicalTrials.gov ↗ · Stomach Cancer, Stomach Cancer Recurrent, Stomach Cancer, Adenocarcinoma	Phase 1/2	Recruiting	Essen Biotech	China
TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer NCT06532812 · ClinicalTrials.gov ↗ · Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic	Phase 1/2	Recruiting	Essen Biotech	China
TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Lung Cancer NCT06538012 · ClinicalTrials.gov ↗ · Lung Cancer, Lung Cancer Metastatic, Lung Cancer, Non-small Cell	Phase 1/2	Recruiting	Essen Biotech	China
Ixovex-1 Single Agent and Combination Therapy NCT06549946 · ClinicalTrials.gov ↗ · Solid Tumor, Head and Neck Cancer	Phase 1/2	Recruiting	Psivac Ltd	UK
A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors NCT06618287 · ClinicalTrials.gov ↗ · Lung Cancer, Breast Cancer	Phase 1/2	Recruiting	Bristol-Myers Squibb	UK, USA
TIL Therapy Combined With Pembrolizumab for Advanced Brain Cancer Including Gliomas and Meningiomas NCT06640582 · ClinicalTrials.gov ↗ · Brain Tumor, Brain Metastases, Brain Cancer	Phase 1/2	Recruiting	Essen Biotech	China
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations NCT06772623 · ClinicalTrials.gov ↗ · Non Small Cell Lung Carcinoma	Phase 1/2	Recruiting	AbbVie	UK, USA, China
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors NCT06795412 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Pyxis Oncology, Inc	USA
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) NCT06843447 · ClinicalTrials.gov ↗ · Ovarian Cancer Recurrent	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors NCT06877650 · ClinicalTrials.gov ↗ · Advanced Malignant Tumors	Phase 1/2	Recruiting	Shanghai JMT-Bio Inc.	China
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer NCT06942234 · ClinicalTrials.gov ↗ · Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer	Phase 1/2	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors NCT07020221 · Pancreatic Ductal Adenocarcinoma, Non Small Cell Lung Cancer, Colorectal Cancer	Phase 1/2	Recruiting	Verastem, Inc.	USA
ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors NCT07158918 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1/2	Recruiting	ABL Bio, Inc.	USA
A Study of YL242 in Subjects With Advanced Solid Tumors NCT07197827 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	USA, China
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies NCT07223047 · Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Recruiting	Bristol-Myers Squibb	USA
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04) NCT07232602 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors NCT07262619 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer	Phase 1/2	Recruiting	Eikon Therapeutics	USA
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors NCT07287917 · ClinicalTrials.gov ↗ · Melanoma (Skin Cancer), HER2-low Hormone Receptor Positive Breast Cancer	Phase 1/2	Recruiting	Aminex Therapeutics, Inc.	USA
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors NCT07287995 · Locally Advanced or Metastatic Malignant Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc.	USA
EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors NCT07410676 · ClinicalTrials.gov ↗ · Cancer, Sarcoma, Leukaemia	Phase 1/2	Recruiting	Essen Biotech	China
N-3C01 Monotherapy and Combination With PD-(L)1 Inhibitors in Advanced Solid Tumors NCT07639450 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Tumors	Phase 1/2	Recruiting	Hefei Xinzhu Biological Technology Co., Ltd.	China
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced Malignancies NCT07644039 · ClinicalTrials.gov ↗ · Advanced Malignancies	Phase 1/2	Recruiting	PharmaMar	USA
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors NCT07730021 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1/2	Recruiting	Astellas Pharma Global Development, Inc.	USA
A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors NCT07749586 · Advanced Solid Tumor	Phase 1/2	Recruiting	Arvinas Inc.	USA
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab NCT07751042 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Strand Therapeutics Inc.	USA
A Study of Sigvotatug Vedotin in Advanced Solid Tumors NCT04389632 · Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors NCT04429542 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer	Phase 1	Recruiting	Bicara Therapeutics	USA
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer NCT04991948 · ClinicalTrials.gov ↗ · Unresectable Metastatic Colorectal Cancer	Phase 1	Recruiting	Celyad Oncology SA	USA
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) NCT05067283 · Advanced Solid Tumors	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA, China
A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors NCT05205109 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Antengene Therapeutics Limited	China
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors NCT05208762 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Esophageal Squamous Cell Carcinoma	Phase 1	Recruiting	Seagen, a wholly owned subsidiary of Pfizer	UK, USA, China
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors NCT05270213 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1	Recruiting	Riboscience, LLC.	USA
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA, China
A Study of ASP3082 in Adults With Advanced Solid Tumors NCT05382559 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Astellas Pharma Inc	USA, China
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3 NCT05614739 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	UK, USA, China
A Study of ASP1002 in Adults for Treatment of Solid Tumors NCT05719558 · Advanced Solid Tumors	Phase 1	Recruiting	Astellas Pharma Global Development, Inc.	USA
A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies NCT05753722 · Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, NSCLC	Phase 1	Recruiting	Incendia Therapeutics	USA
DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors NCT05785754 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	DynamiCure Biotechnology	USA
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981 · Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer	Phase 1	Recruiting	Sairopa B.V.	USA
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors NCT05907980 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Recruiting	Chugai Pharmaceutical	USA
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors NCT05954312 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	Vividion Therapeutics, Inc.	USA
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors NCT06004245 · Advanced Solid Tumors, Colorectal Cancer	Phase 1	Recruiting	Vividion Therapeutics, Inc.	UK, USA, China
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors NCT06108050 · Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1	Recruiting	Jazz Pharmaceuticals	USA
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors NCT06234397 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Hanmi Pharmaceutical Company Limited	USA
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumor	Phase 1	Recruiting	Pliant Therapeutics, Inc.	USA
Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer NCT06343402 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer, NSCLC	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors NCT06384352 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd.	USA, China
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	USA
ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) NCT06415487 · Locally Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1	Recruiting	Acepodia Biotech, Inc.	USA
First In Human Study of CX-801 in Advanced Solid Tumors NCT06462794 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1	Recruiting	CytomX Therapeutics	USA
An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors NCT06480552 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	Teva Branded Pharmaceutical Products R&D LLC	USA
Study of XB010 in Subjects With Solid Tumors NCT06545331 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer	Phase 1	Recruiting	Exelixis	UK, USA
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD) NCT06551142 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Recruiting	GlaxoSmithKline	UK, USA
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 · ClinicalTrials.gov ↗ · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer	Phase 1	Recruiting	Eli Lilly and Company	USA
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma NCT06600321 · ClinicalTrials.gov ↗ · Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma	Phase 1	Recruiting	Alnylam Pharmaceuticals	USA
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors NCT06724016 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Hanmi Pharmaceutical Company Limited	USA
Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer NCT06736379 · ClinicalTrials.gov ↗ · Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors	Phase 1	Recruiting	VLP Therapeutics	USA
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations NCT06835569 · ClinicalTrials.gov ↗ · Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, NSCLC (Non-small Cell Lung Cancer)	Phase 1	Recruiting	Alterome Therapeutics, Inc.	USA
Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC NCT06868732 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer	Phase 1	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors NCT06880549 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Recruiting	ModernaTX, Inc.	USA
BBO-11818 in Adult Subjects With KRAS Mutant Cancer NCT06917079 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma	Phase 1	Recruiting	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)	USA
IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) NCT06940440 · ClinicalTrials.gov ↗ · Advanced Or Metastatic Merkel Cell Carcinoma	Phase 1	Recruiting	TuHURA Biosciences, Inc.	USA
Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumors NCT06960395 · ClinicalTrials.gov ↗ · Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR	Phase 1	Recruiting	Vir Biotechnology, Inc.	USA
Study of HC006 in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumors NCT06963814 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1	Recruiting	HC Biopharma Inc.	China
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies NCT06994806 · ClinicalTrials.gov ↗ · Solid Tumor Malignancies	Phase 1	Recruiting	Kumquat Biosciences Inc.	USA
A Study of LY4175408 in Participants With Advanced Cancer NCT07046923 · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Endometrial Neoplasms	Phase 1	Recruiting	Eli Lilly and Company	USA, China
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors NCT07094113 · ClinicalTrials.gov ↗ · KRAS Altered Advanced or Metastatic Solid Tumors	Phase 1	Recruiting	Amgen	UK, USA, China
Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors NCT07128303 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Gilead Sciences	USA
M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors NCT07166601 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	EMD Serono Research & Development Institute, Inc.	USA
A Study of DS5361b in Participants With Advanced Solid Tumors NCT07182591 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Recruiting	Daiichi Sankyo	USA
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer NCT07227168 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma HNSCC, Non-Small Cell Lung Cancer NSCLC, Esophageal Cancer	Phase 1	Recruiting	Sutro Biopharma, Inc.	USA
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) NCT07247110 · ClinicalTrials.gov ↗ · Malignant Neoplasm	Phase 1	Recruiting	Merck Sharp & Dohme LLC	USA
Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer NCT07484022 · ClinicalTrials.gov ↗ · Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma	Phase 1	Recruiting	Generate Biomedicines	USA
Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer NCT07652242 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer (TNBC)	Phase 1	Recruiting	Immunomic Therapeutics, Inc.	USA
The Immune Assessment of PD-1 Antibody Therapy in Tumor NCT06693440 · ClinicalTrials.gov ↗ · Efficacy, Team, Adverse Event	Observational	Recruiting	Quanli Gao	China
Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study NCT07010393 · ClinicalTrials.gov ↗ · Thyroid Neoplasms	Phase 4	Not yet open	Fujian Medical University	China
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer NCT07318883 · Squamous NSCLC	Phase 2/3	Not yet open	Shanghai Henlius Biotech	China
Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma NCT04622566 · ClinicalTrials.gov ↗ · Mucosal Melanoma, Neoadjuvant Treatment	Phase 2	Not yet open	Peking University Cancer Hospital & Institute	China
Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma NCT06814067 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC	Phase 2	Not yet open	Fudan University	China
A Prospective, Single-center, Phase II Study of Sacituzumab Tirumotecan in Combination With Pembrolizumab for Neoadjuvant Treatment of Triple-Negative Breast Cancer (TNBC) NCT07054242 · ClinicalTrials.gov ↗ · Neoadjuvant Therapy, Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer	Phase 2	Not yet open	Yantai Yuhuangding Hospital	China
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer NCT07159217 · ClinicalTrials.gov ↗ · Biliary Tract Cancer, Disitamab Vedotin, Lenvatinib	Phase 2	Not yet open	Peking Union Medical College Hospital	China
Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer With Liver Metastases NCT07466927 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer	Phase 2	Not yet open	Fudan University	China
Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer NCT07808151 · ClinicalTrials.gov ↗ · Colon Cancer, Microsatellite Stable (MSS) Colon Cancer, Proficient Mismatch Repair (pMMR) Colon Cancer	Phase 2	Not yet open	Solstice Oncology, Inc.	UK, USA
A Multicenter, Prospective, Randomized, Open-label Phase Ib/II Study of Celecoxib Plus Pembrolizumab and Gemcitabine/Cisplatin Versus Pembrolizumab and Gemcitabine/Cisplatin in Patients With CK5/6-High Unresectable Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma NCT07632235 · ClinicalTrials.gov ↗ · Intrahepatic Cholangiocarcinoma (Icc)	Phase 1/2	Not yet open	Shanghai 6th People's Hospital	China
Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy NCT07762703 · ClinicalTrials.gov ↗ · Triple-Negative Breast Cancer (TNBC)	Phase 1/2	Not yet open	BreakBio Corp	USA
Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy NCT07762716 · ClinicalTrials.gov ↗ · Glioblastoma (GBM)	Phase 1/2	Not yet open	BreakBio Corp	USA
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer NCT07217496 · ClinicalTrials.gov ↗ · Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma	Phase 1	Not yet open	ImmunityBio, Inc.	USA
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345 · ClinicalTrials.gov ↗ · Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer	Phase 1	Not yet open	Sutro Biopharma, Inc.	USA
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4 NCT07218003 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer	Phase 1	By invitation	Rondo Therapeutics	USA
Development and Analysis of a Stool Bank for Cancer Patients NCT04291755 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal	Observational	By invitation	Persephone Biosciences	USA
Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites NCT05745233 · ClinicalTrials.gov ↗ · Malignant Ascites	Not applicable	By invitation	China Medical University Hospital	China
Phase 0 Master Protocol for CIVO Intratumoral Microdosing of Anti-Cancer Therapies NCT04541108 · ClinicalTrials.gov ↗ · Solid Tumor	Phase EARLY_PHASE1	Active, closed	Presage Biosciences	USA
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery NCT02506153 · Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Ireland
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma NCT02811861 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 3	Active, closed	Eisai Inc.	Ireland, UK, USA
A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations NCT03390504 · ClinicalTrials.gov ↗ · Urothelial Cancer	Phase 3	Active, closed	Janssen Research & Development, LLC	UK, USA, China
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) NCT03425643 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) NCT03553836 · ClinicalTrials.gov ↗ · Melanoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676) NCT03711032 · ClinicalTrials.gov ↗ · High-risk Non-muscle Invasive Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) NCT03725059 · Breast Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689) NCT03765918 · Head and Neck Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063 · ClinicalTrials.gov ↗ · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303) NCT03924895 · Urinary Bladder Cancer, Muscle-invasive	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA
A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer NCT04194944 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Eli Lilly and Company	UK, China
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer NCT04223856 · ClinicalTrials.gov ↗ · Urothelial Cancer	Phase 3	Active, closed	Astellas Pharma Global Development, Inc.	UK, USA, China
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992) NCT04241185 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · ClinicalTrials.gov ↗ · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) NCT04624204 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) NCT04634877 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma NCT04657991 · ClinicalTrials.gov ↗ · Melanoma	Phase 3	Active, closed	Pfizer	UK, USA
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) NCT04700124 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) NCT04736706 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) NCT04895358 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) NCT04956692 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA
A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations NCT05048797 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). NCT05116189 · ClinicalTrials.gov ↗ · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) NCT05155254 · Metastatic Melanoma, Unresectable Melanoma	Phase 3	Active, closed	IO Biotech	UK, USA
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations NCT05215340 · Metastatic Non Small Cell Lung Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022) NCT05239728 · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) NCT05239741 · ClinicalTrials.gov ↗ · Colorectal Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma NCT05352672 · ClinicalTrials.gov ↗ · Melanoma	Phase 3	Active, closed	Regeneron Pharmaceuticals	Ireland, UK, USA
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382286 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer, PD-L1 Positive	Phase 3	Active, closed	Gilead Sciences	UK, USA
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer NCT05502237 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) NCT05555732 · ClinicalTrials.gov ↗ · Metastatic Non Small Cell Lung Cancer	Phase 3	Active, closed	Daiichi Sankyo	UK, USA, China
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery NCT05608291 · ClinicalTrials.gov ↗ · Melanoma	Phase 3	Active, closed	Regeneron Pharmaceuticals	Ireland, UK, USA
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) NCT05609968 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) NCT05629585 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, China
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations NCT05687266 · NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) NCT05722015 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, China
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study NCT05899049 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 3	Active, closed	Merck Sharp & Dohme LLC	China
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 NCT05911295 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	Ireland, UK, USA, China
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) NCT05933577 · ClinicalTrials.gov ↗ · Melanoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. NCT05984277 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) NCT06077760 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, USA
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer NCT06112379 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment NCT06151574 · ClinicalTrials.gov ↗ · Lung Cancer, Non-squamous, Non-small Cell	Phase 3	Active, closed	Boehringer Ingelheim	UK, USA, China
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer NCT06311721 · Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer	Phase 3	Active, closed	Amgen	UK, USA
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer NCT06348199 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IV	Phase 3	Active, closed	Samsung Bioepis Co., Ltd.	India
A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT06448312 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC) NCT06472076 · Lung Cancer, Non-Small Cell	Phase 3	Active, closed	GlaxoSmithKline	USA, India, China
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06) NCT06635824 · ClinicalTrials.gov ↗ · PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC	Phase 3	Active, closed	Genmab	Ireland, UK, USA
A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84) NCT06698042 · Lung Cancer, Non-Small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer NCT06711900 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	China
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) NCT06726265 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Immutep S.A.S.	Ireland, UK, USA, India
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 NCT04534205 · Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer	Phase 2/3	Active, closed	BioNTech SE	UK, USA
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma NCT05987332 · ClinicalTrials.gov ↗ · Metastatic Uveal Melanoma	Phase 2/3	Active, closed	IDEAYA Biosciences	UK, USA
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT06082167 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2/3	Active, closed	Exelixis	UK, USA
INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC NCT06295731 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma (HNSCC)	Phase 2/3	Active, closed	Inhibrx Biosciences, Inc	UK, USA, China
A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer NCT06984588 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2/3	Active, closed	TJ Biopharma Co., Ltd.	China
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors NCT03228667 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma	Phase 2	Active, closed	ImmunityBio, Inc.	USA
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144 · Hodgkin Lymphoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors NCT03485209 · ClinicalTrials.gov ↗ · Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	UK, USA
A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer NCT03505320 · ClinicalTrials.gov ↗ · Pharmacokinetics of Zolbetuximab, Gastric Cancer, Gastro-esophageal Junction (GEJ) Cancer	Phase 2	Active, closed	Astellas Pharma Global Development, Inc.	USA
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread NCT03547973 · Metastatic Urothelial Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors NCT03836352 · Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer	Phase 2	Active, closed	ImmunoVaccine Technologies, Inc. (IMV Inc.)	USA
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) NCT03897881 · Melanoma	Phase 2	Active, closed	ModernaTX, Inc.	USA
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) NCT04225117 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Malignant Solid Tumors	Phase 2	Active, closed	Astellas Pharma Global Development, Inc.	USA
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) NCT04379596 · Gastric Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, China
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma NCT04417166 · ClinicalTrials.gov ↗ · Lymphoma, Extranodal NK-T-Cell	Phase 2	Active, closed	International Extranodal Lymphoma Study Group (IELSG)	China
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers NCT04430738 · Colorectal Carcinoma, Gastric Adenocarcinoma, GEJ Adenocarcinoma	Phase 2	Active, closed	Seagen, a wholly owned subsidiary of Pfizer	USA
Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) NCT04675294 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	ALX Oncology Inc.	UK, USA
Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04) NCT04675333 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	ALX Oncology Inc.	UK, USA
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer NCT04736173 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer	Phase 2	Active, closed	Arcus Biosciences, Inc.	USA
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008). NCT04895722 · ClinicalTrials.gov ↗ · Colorectal Cancer	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016) NCT04976634 · ClinicalTrials.gov ↗ · Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA
A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients NCT05078931 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) NCT05186974 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer NCT05217446 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer	Phase 2	Active, closed	Pfizer	UK, USA
A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer NCT05318573 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma, Advanced Non Small Cell Lung Cancer	Phase 2	Active, closed	Fujifilm Pharmaceuticals U.S.A., Inc.	USA
Neoadjuvant/Adjuvant Pembrolizumab Plus Chemotherapy NCT05383716 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Neoadjuvant Therapy, Immune Checkpoint Inhibitor	Phase 2	Active, closed	Peking Union Medical College Hospital	China
ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer NCT05446298 · ClinicalTrials.gov ↗ · Ovarian Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma	Phase 2	Active, closed	OncoC4, Inc.	USA
A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer NCT05565378 · Lung Cancer, Non-Small Cell	Phase 2	Active, closed	GlaxoSmithKline	UK, USA
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Microsatellite Stable Locally Advanced Rectal Cancer NCT05585814 · ClinicalTrials.gov ↗ · Locally Advanced Rectal Cancer	Phase 2	Active, closed	Shanghai Changzheng Hospital	China
Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) NCT05599789 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic	Phase 2	Active, closed	Peking Union Medical College Hospital	China
SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid Tumors NCT05642780 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 2	Active, closed	Klus Pharma Inc.	USA, China
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01) NCT05724329 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinomas	Phase 2	Active, closed	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients NCT05751187 · ClinicalTrials.gov ↗ · Non-squamous NSCLC	Phase 2	Active, closed	Shanghai Chest Hospital	China
A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma NCT05805501 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, China
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer NCT05852691 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	Hoffmann-La Roche	USA
Pembrolizumab and Chemotherapy Neoadjuvant/Adjuvant of NSCLC NCT05894889 · ClinicalTrials.gov ↗ · Stage IIIB(N2) Non-small Cell Lung Cancer, Stage IIA Non-small Cell Lung Cancer, Stage IIB Non-small Cell Lung Cancer	Phase 2	Active, closed	Peking University	China
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer	Phase 2	Active, closed	Taiho Oncology, Inc.	USA
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS NCT06008093 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 2	Active, closed	AstraZeneca	USA
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) NCT06099782 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) NCT06225596 · ClinicalTrials.gov ↗ · Metastatic Urothelial Cancer	Phase 2	Active, closed	BicycleTx Limited	UK, USA, China
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC NCT06246110 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Eikon Therapeutics	USA
A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). NCT06307431 · Renal Cell Carcinoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China
A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65) NCT06504394 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory, Primary Mediastinal Large B-cell Lymphoma Recurrent	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen NCT06699836 · ClinicalTrials.gov ↗ · Metastatic Colorectal Cancer (mCRC)	Phase 2	Active, closed	CytoDyn, Inc.	USA
Study of NEO-201 in Solid Tumors Expansion Cohorts NCT03476681 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Cancer	Phase 1/2	Active, closed	Precision Biologics, Inc	USA
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors NCT03611868 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Melanoma or Advanced Solid Tumors, Melanoma, Uveal Melanoma	Phase 1/2	Active, closed	Ascentage Pharma Group Inc.	USA
Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors NCT03647163 · ClinicalTrials.gov ↗ · Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma	Phase 1/2	Active, closed	Vyriad, Inc.	USA
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1 NCT03785249 · ClinicalTrials.gov ↗ · Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease	Phase 1/2	Active, closed	Mirati Therapeutics Inc.	USA
Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors NCT04041310 · ClinicalTrials.gov ↗ · Solid Tumor, Adult	Phase 1/2	Active, closed	Nouscom SRL	UK, USA
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · ClinicalTrials.gov ↗ · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC NCT04140526 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma	Phase 1/2	Active, closed	OncoC4, Inc.	USA
ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors NCT04205227 · ClinicalTrials.gov ↗ · Cancer, Melanoma, Ovary Cancer	Phase 1/2	Active, closed	ENB Therapeutics, Inc	USA
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC NCT04251117 · HCC	Phase 1/2	Active, closed	Geneos Therapeutics	USA
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors NCT04305795 · ClinicalTrials.gov ↗ · Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma	Phase 1/2	Active, closed	Rakuten Medical, Inc.	USA
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies NCT04521413 · ClinicalTrials.gov ↗ · Advanced Solid Malignancies	Phase 1/2	Active, closed	Treadwell Therapeutics, Inc	USA
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies NCT04561362 · ClinicalTrials.gov ↗ · Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms	Phase 1/2	Active, closed	BicycleTx Limited	UK, USA
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A) NCT04626479 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03) NCT04626518 · ClinicalTrials.gov ↗ · Carcinoma, Renal Cell	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) NCT04956640 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Endometrial Neoplasms	Phase 1/2	Active, closed	Eli Lilly and Company	USA
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme NCT05053880 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma Multiforme(GBM)	Phase 1/2	Active, closed	Accendatech USA Inc.	USA
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies NCT05081609 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1/2	Active, closed	Ascendis Pharma Oncology Division A/S	USA
A Study of NDI 1150-101 in Patients With Solid Tumors NCT05128487 · ClinicalTrials.gov ↗ · Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	Phase 1/2	Active, closed	Nimbus Saturn, Inc.	USA
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors NCT05180799 · ClinicalTrials.gov ↗ · NSCLC, Melanoma	Phase 1/2	Active, closed	BioAtla, Inc.	USA
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. NCT05271318 · ClinicalTrials.gov ↗ · Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma	Phase 1/2	Active, closed	TILT Biotherapeutics Ltd.	USA
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors NCT05438420 · ClinicalTrials.gov ↗ · Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer	Phase 1/2	Active, closed	Qurient Co., Ltd.	USA
A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors NCT05585320 · Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)	Phase 1/2	Active, closed	Immuneering Corporation	USA
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04) NCT05845814 · ClinicalTrials.gov ↗ · Metastatic Urothelial Carcinoma, Urothelial Neoplasms	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors NCT05887492 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Solid Tumors, Adult, Lung Cancer	Phase 1/2	Active, closed	Tango Therapeutics, Inc.	USA
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers. NCT06116136 · ClinicalTrials.gov ↗ · MSI-H/dMMR Gastroesophageal-junction Cancer, MSI-H/dMMR Gastric Cancer	Phase 1/2	Active, closed	Servier Bio-Innovation LLC	UK, USA, China
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005) NCT06305767 · ClinicalTrials.gov ↗ · Bladder Cancer	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04) NCT06483334 · Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma	Phase 1/2	Active, closed	Merck Sharp & Dohme LLC	UK, USA
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations NCT06644768 · Non-small Cell Lung Cancer, Lung Cancer	Phase 1/2	Active, closed	Daiichi Sankyo	USA, China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma NCT06784648 · ClinicalTrials.gov ↗ · Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated	Phase 1/2	Active, closed	BioInvent International AB	UK
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer NCT02779751 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Breast Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab NCT03161431 · ClinicalTrials.gov ↗ · Melanoma Stage III, Melanoma Stage IV	Phase 1	Active, closed	Syntrix Biosystems, Inc.	USA
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors NCT03313778 · ClinicalTrials.gov ↗ · Solid Tumors	Phase 1	Active, closed	ModernaTX, Inc.	UK, USA
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC) NCT03319940 · Small Cell Lung Carcinoma	Phase 1	Active, closed	Amgen	UK, USA
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors NCT03530397 · ClinicalTrials.gov ↗ · Selected Advanced Solid Tumors	Phase 1	Active, closed	MedImmune LLC	USA
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy NCT03589339 · ClinicalTrials.gov ↗ · Radiotherapy, Immunotherapy, Microsatellite Instability-High Solid Malignant Tumour	Phase 1	Active, closed	Nanobiotix	USA
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors NCT03872947 · ClinicalTrials.gov ↗ · Solid Tumor, Colorectal Cancer, Cholangiocarcinoma	Phase 1	Active, closed	Toray Industries, Inc	USA
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer NCT04042701 · Breast Cancer, Non-small Cell Lung Carcinoma	Phase 1	Active, closed	Daiichi Sankyo	UK, USA
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) NCT04185883 · ClinicalTrials.gov ↗ · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation	Phase 1	Active, closed	Amgen	UK, USA
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers NCT04485013 · Cancer	Phase 1	Active, closed	Tizona Therapeutics, Inc	USA
Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) NCT04526691 · ClinicalTrials.gov ↗ · Advanced or Metastatic NSCLC	Phase 1	Active, closed	Daiichi Sankyo	USA
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer NCT04958239 · ClinicalTrials.gov ↗ · Neoplasms	Phase 1	Active, closed	Boehringer Ingelheim	USA, China
A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) NCT05030506 · ClinicalTrials.gov ↗ · Renal Cell Carcinoma	Phase 1	Active, closed	Merck Sharp & Dohme LLC	China
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT05117476 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, NSCLC	Phase 1	Active, closed	Cullinan Therapeutics Inc.	USA
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors NCT05215574 · ClinicalTrials.gov ↗ · Pancreatic Cancer, Breast Cancer, Gastric Cancer	Phase 1	Active, closed	NGM Biopharmaceuticals, Inc	USA
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab NCT05378425 · Cancer, Tumor, Solid, Advanced Solid Tumor	Phase 1	Active, closed	Nectin Therapeutics Ltd	USA
A Study of MK-1484 as Monotherapy and in Combination With Pembrolizumab (MK-3475) In Advanced or Metastatic Solid Tumors (MK-1484-001) NCT05382325 · ClinicalTrials.gov ↗ · Advanced or Metastatic Solid Tumors	Phase 1	Active, closed	Merck Sharp & Dohme LLC	USA
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors NCT05537740 · Advanced Solid Tumors	Phase 1	Active, closed	Bayer	UK, USA, China
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers NCT05544929 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell	Phase 1	Active, closed	Novartis Pharmaceuticals	USA, China
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors NCT05581004 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC	Phase 1	Active, closed	Genentech, Inc.	USA
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors NCT05614102 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1	Active, closed	Bayer	UK, USA, China
A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors NCT05653882 · ClinicalTrials.gov ↗ · Solid Tumor, Non Small Cell Lung Cancer, Melanoma	Phase 1	Active, closed	Asher Biotherapeutics, Inc.	USA
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors NCT05787587 · Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer	Phase 1	Active, closed	IDEAYA Biosciences	USA
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. NCT05838768 · ClinicalTrials.gov ↗ · MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers	Phase 1	Active, closed	Novartis Pharmaceuticals	UK, USA, China
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001) NCT05853367 · Metastatic Solid Tumors, Advanced Solid Tumors	Phase 1	Active, closed	Merck Sharp & Dohme LLC	USA
A Study of GRC 54276 in Participants With Advanced Solid Tumors and Lymphomas. NCT05878691 · ClinicalTrials.gov ↗ · Advanced Solid Tumor, Lymphoma	Phase 1	Active, closed	Glenmark Specialty S.A.	USA, India
Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer NCT06125197 · Lung Cancer	Phase 1	Active, closed	TILT Biotherapeutics Ltd.	USA
A Study of DM919 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT06328673 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1	Active, closed	D2M Biotherapeutics Inc.	USA, China
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). NCT06333951 · ClinicalTrials.gov ↗ · Thoracic Tumors, Non-small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA, China
A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients NCT06540391 · ClinicalTrials.gov ↗ · Melanoma	Phase 1	Active, closed	Microbiotica Ltd	UK
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors NCT06607185 · ClinicalTrials.gov ↗ · Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer	Phase 1	Active, closed	Eli Lilly and Company	USA
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone NCT06806852 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 1	Active, closed	Boehringer Ingelheim	UK, USA
A Dose Escalation and Expansion Trial With BYON4228 Alone and in Combination in Patients With Advanced or Metastatic Solid Tumors NCT06932952 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1	Active, closed	Byondis B.V.	UK
Demographics, Clinical Characteristics and Outcomes in Resected Non-Small Cell Lung Cancer Patients Receiving Immunotherapy in Europe and Canada NCT07718139 · Non-Small Cell Lung Cancer	Observational	Active, closed	Bristol-Myers Squibb	UK

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Pembrolizumab across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

3 single-substance products containing Pembrolizumab on the HPRA medicines list.

KEYTRUDA 25 mg/mL concentrate for solution for infusionMerck Sharp & Dohme BV, · EU/1/15/1024/002-003
KEYTRUDA 395 mg solution for injectionMerck Sharp & Dohme BV, · EU/1/15/1024/004
KEYTRUDA 790 mg solution for injectionMerck Sharp & Dohme BV, · EU/1/15/1024/005

All 3 Irish products →

Supply shortages

No entry for Pembrolizumab in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Pembrolizumab

360 conditions

Non-small Cell Lung Cancer23 Advanced Solid Tumor23 Non-Small Cell Lung Cancer21 Melanoma20 Carcinoma, Non-Small-Cell Lung17 Non Small Cell Lung Cancer16 Solid Tumor15 Advanced Solid Tumors14 NSCLC13 Head and Neck Squamous Cell Carcinoma13 Breast Cancer12 Lung Cancer11

All 360 conditions

Condition (as registered)	Trials
Non-small Cell Lung Cancer	23
Advanced Solid Tumor	23
Non-Small Cell Lung Cancer	21
Melanoma	20
Carcinoma, Non-Small-Cell Lung	17
Non Small Cell Lung Cancer	16
Solid Tumor	15
Advanced Solid Tumors	14
NSCLC	13
Head and Neck Squamous Cell Carcinoma	13
Breast Cancer	12
Lung Cancer	11
Colorectal Cancer	11
Cancer	10
Gastric Cancer	8
Metastatic Solid Tumor	8
Cervical Cancer	7
Carcinoma, Renal Cell	6
Solid Tumors	6
Renal Cell Carcinoma	6
Urothelial Carcinoma	6
Metastatic Urothelial Carcinoma	6
Solid Tumor, Adult	6
HNSCC	6
Head and Neck Cancer	6
Advanced or Metastatic Solid Tumors	6
Advanced Cancer	6
Triple Negative Breast Cancer	5
Ovarian Cancer	5
Endometrial Neoplasms	5
Esophageal Squamous Cell Carcinoma	5
Pancreatic Ductal Adenocarcinoma	5
Bladder Cancer	5
Metastatic Cancer	5
Esophageal Cancer	5
Breast Neoplasms	4
Recurrent Head and Neck Squamous Cell Carcinoma	4
Squamous Cell Carcinoma of Head and Neck	4
Biliary Tract Cancer	4
Urinary Bladder Neoplasms	4
Neoplasm Metastasis	4
Urothelial Cancer	4
Triple Negative Breast Neoplasms	4
Locally Advanced or Metastatic Solid Tumors	4
Advanced Non-Small Cell Lung Cancer	3
Endometrial Cancer	3
Lymphoma	3
Metastatic Melanoma	3
Unresectable Melanoma	3
Metastatic Non-small Cell Lung Cancer	3
Non-small Cell Lung Cancer (NSCLC)	3
Colorectal Neoplasms	3
Non-squamous Non-small Cell Lung Cancer	3
Non-Small Cell Lung Cancer (NSCLC)	3
Lung Adenocarcinoma	3
Cutaneous Melanoma	3
Hepatocellular Carcinoma	3
Gastric Adenocarcinoma	3
Melanoma Stage III	3
Melanoma Stage IV	3
Locally Advanced Solid Tumor	3
Immunotherapy	3
Neoadjuvant Therapy	3
Metastatic Non-Small Cell Lung Cancer	2
Carcinoma, Non-Small Cell Lung	2
Metastatic Head and Neck Squamous Cell Carcinoma	2
Carcinoma, Ovarian Epithelial	2
Hodgkin Lymphoma	2
Metastatic Urothelial Cancer	2
Metastatic Non Small Cell Lung Cancer	2
Squamous Cell Carcinoma of the Head and Neck	2
Lung Cancer, Non-Small Cell	2
Small Cell Lung Carcinoma	2
Locally Advanced Urothelial Carcinoma	2
Neoplasms	2
Colon Cancer	2
Advanced Melanoma	2
MSI-H/dMMR Gastric Cancer	2
Esophageal Squamous Cell Cancer	2
Head and Neck Squamous Cell Cancer	2
NSCLC (Non-small Cell Lung Cancer)	2
Carcinoma, Non-Small-Cell Lung (NSCLC)	2
Small Cell Lung Cancer	2
Colorectal Cancer (CRC)	2
HER2-positive Gastric Cancer	2
Lung Cancer, Non-squamous, Non-small Cell	2
Melanoma (Skin Cancer)	2
Malignant Neoplasm	2
Pancreatic Adenocarcinoma	2
Advanced Or Metastatic Merkel Cell Carcinoma	2
Esophageal Adenocarcinoma	2
Advanced Solid Malignancies	2
Locally Advanced or Metastatic Malignant Solid Tumors	2
Refractory Cancer	2
Gastroesophageal Junction (GEJ) Adenocarcinoma	2
Triple Negative Breast Cancer (TNBC)	2
Head and Neck Squamous Cell Carcinoma HNSCC	2
Non-Small Cell Lung Cancer NSCLC	2
Ovarian Neoplasms	2
PDAC - Pancreatic Ductal Adenocarcinoma	2
CRC (Colorectal Cancer)	2
Brain Tumor	2
Pancreatic Cancer	2
Platinum-resistant Ovarian Cancer	2
Advanced Urothelial Carcinoma	2
Solid Tumor Malignancies	2
Lung Cancer, Non-small Cell	2
Lung Cancer Metastatic	2
Primary Peritoneal Carcinoma	2
Fallopian Tube Cancer	2
Radiotherapy	2
Liver Cancer	2
Pembrolizumab	2
Head and Neck Neoplasms	1
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Hematologic Malignancies	1
Clinical Stage III Cutaneous Melanoma AJCC v8	1
Clinical Stage IV Cutaneous Melanoma AJCC v8	1
Metastatic Cutaneous Melanoma	1
Metastatic Mucosal Melanoma	1
Urinary Bladder Cancer, Muscle-invasive	1
KRAS G12C Lung Cancer	1
Unresectable Solid Tumor	1
Clear Cell Renal Cell Carcinoma	1
Metastatic Renal Cell Carcinoma	1
Stage III Renal Cell Cancer AJCC v8	1
Stage IV Renal Cell Cancer AJCC v8	1
Unresectable Renal Cell Carcinoma	1
Triple-Negative Breast Cancer	1
Fallopian Tube Neoplasms	1
PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC	1
Non-small Cell Lung Carcinoma	1
Unresectable Head and Neck Squamous Cell Carcinoma	1
Metastatic Head and Neck Cancer	1
Recurrent Head and Neck Cancer	1
Classical Hodgkin Lymphoma	1
High-risk Muscle Invasive Urothelial Carcinoma	1
Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer	1
Advanced Non-small Cell Lung Cancer, HER2 Mutation	1
HER2 Negative Breast Neoplasms	1
Renal Cell Cancer	1
High Grade Ovarian Serous Adenocarcinoma	1
Ureteral Neoplasms	1
PD-L1 Positive	1
Microsatellite Stable (MSS) Colon Cancer	1
Proficient Mismatch Repair (pMMR) Colon Cancer	1
Metastatic Uveal Melanoma	1
Muscle-invasive Bladder Cancer	1
HPV Positive Oropharyngeal Squamous Cell Carcinoma	1
KRAS Altered Advanced or Metastatic Solid Tumors	1
MSI-H/dMMR Gastroesophageal-junction Cancer	1
Exocrine Pancreatic Cancer	1
Carcinoma, Squamous Cell of Head and Neck	1
Melanoma Metastatic	1
Melanoma of Skin	1
Melanoma BRAF V600E/K Mutated	1
Melanoma Recurrent	1
Metastatic Non-small Cell Lung Cancer With MTAP Deletion	1
Gastroesophageal Junction Cancer	1
Metastatic Colorectal Cancer	1
Classical Hodgkin Lymphoma Recurrent	1
Classical Hodgkin Lymphoma Refractory	1
Primary Mediastinal Large B-cell Lymphoma Recurrent	1
Primary Mediastinal Large B-cell Lymphoma Refractory	1
High-risk Non-muscle Invasive Bladder Cancer	1
Melanoma, Cutaneous Malignant	1
HR Low-Positive/HER2-Negative Breast Neoplasms	1
Malignant Solid Tumor	1
Colorectal Adenocarcinoma	1
Head and Neck Squamous Cell Carcinoma (HNSCC)	1
Lung Neoplasms	1
Kirsten Rat Sarcoma (KRAS) pG12C Mutation	1
Urinary Bladder Neoplasm	1
Hormone Receptor Positive, HER2-negative Neoplasms	1
Hormone Receptor Positive, HER2-low Neoplasms	1
Carcinoma, Transitional Cell	1
Urothelial Neoplasms	1
MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers	1
Lung Squamous Cell Carcinoma	1
Glioblastoma	1
Gastroesophageal Junction Adenocarcinoma	1
Advanced Malignant Neoplasm	1
Non Small Cell Lung Carcinoma	1
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer	1
Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer	1
Metastatic Gastric Adenocarcinoma or Cancer	1
Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Non-Hodgkin Lymphoma	1
Peripheral T-cell Lymphoma (PTCL)	1
Ovarian Cancer Recurrent	1
Metastatic Solid Tumors	1
Melanoma Stage IIIB-IV	1
Malignant Melanoma (Cutaneous)	1
Squamous Non-small Cell Lung Cancer	1
Tumor, Solid	1
Colorectal Carcinoma	1
GEJ Adenocarcinoma	1
Relapsed Diffuse Large B-cell Lymphoma	1
Refractory Diffuse Large B-cell Lymphoma	1
Pancreatic Ductal Adenocarcinoma (PDAC)	1
Prostate Cancer	1
HCC	1
Locally Advanced or Metastatic Non-Small Cell Lung Cancer	1
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	1
Muscle-Invasive Bladder Carcinoma	1
Lung Neoplasm Malignant	1
CRC, Colorectal Cancer	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
Biliary Tract Cancer (BTC)	1
Selected Advanced Solid Tumors	1
HPV-Related Carcinoma	1
HPV-Related Malignancy	1
Recurrent Cervical Carcinoma	1
Non-Small Cell Lung Cancer, NSCLC	1
KRAS, NRAS, HRAS-mutated NSCLC	1
KRAS G12C-mutated Solid Tumors, Lung Cancer	1
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
Brain Metastases, Adult	1
Head and Neck Cancers- Squamous Cell	1
Head & Neck Squamous Cell Carcinoma	1
Uterine Cancer	1
Non-squamous, Non-Small Cell Lung Cancer	1
Non-Squamous Non Small Cell Lung Cancer	1
Pharmacokinetics of Zolbetuximab	1
Gastro-esophageal Junction (GEJ) Cancer	1
Pharmacokinetics of Oxaliplatin	1
Triple-Negative Breast Cancer (TNBC)	1
Metastatic Head and Neck Carcinoma	1
Uterine Cervical Neoplasms	1
Cholangiocarcinoma	1
Recurrent Glioblastoma Multiforme(GBM)	1
Renal Cell Carcinoma (Kidney Cancer)	1
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Advanced or Metastatic Solid Tumor	1
Platinum-refractory Ovarian Carcinoma	1
Platinum-Resistant Fallopian Tube Carcinoma	1
Platinum-Resistant Primary Peritoneal Carcinoma	1
Advanced Urothelial Cancer	1
Advanced Non Small Cell Lung Cancer	1
Carcinoma, Colorectal	1
Solid Tumors, Adult	1
Malignant Melanoma	1
Gastroesophageal Junction	1
Gastroesophageal Adenocarcinoma	1
Esophageal Neoplasms	1
Glioblastoma (GBM)	1
SMARCA4-Deficient Tumor	1
MSI-H or dMMR Advanced Solid Tumors	1
MSI-H/dMMR Colorectal Cancer	1
Unresectable Metastatic Colorectal Cancer	1
Nonsquamous Non Small Cell Lung Cancer	1
Squamous Non Small Cell Lung Cancer	1
Metastatic Colorectal Cancer (mCRC)	1
HER2-low Hormone Receptor Positive Breast Cancer	1
Thoracic Tumors	1
Metastatic Urothelial Carcinoma (UC)	1
Advanced/Metastatic Solid Tumors	1
Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer	1
Siewert Type 1 GEJ Cancer	1
Neuroendocrine Carcinoma	1
Renal Cell Carcinoma (RCC)	1
High Grade Serous Adenocarcinoma of Ovary	1
Microsatellite Instability-High Solid Malignant Tumour	1
Metastasis From Malignant Tumor of Liver	1
EGFR Positive Solid Tumors	1
EGFR	1
KRAS G12C	1
High Grade Epithelial Ovarian Cancer	1
High Grade Serous Ovarian Cancer	1
Locally Advanced or Metastatic HER2-Expressing Cancers	1
Ovary Cancer	1
Metastatic Head-and-neck Squamous-cell Carcinoma	1
Locally Advanced Cutaneous Squamous Cell Carcinoma	1
Metastatic Cutaneous Squamous Cell Carcinoma	1
Soft Tissue Sarcoma (STS)	1
Platinum-resistant Ovarian Cancer (PROC)	1
Neoplasm Malignant	1
Squamous Cell Carcinoma of Anal Canal	1
Squamous Cell Carcinoma of the Lung	1
Hepatocellular Cancer	1
Gastroesophageal-junction Cancer	1
Monoclonal Antibody	1
Small Cell and Non-small Cell Lung Cancer	1
Squamous Cell Carcinoma of Oral Cavity	1
Non Small Cell Lung Cancer (Squamous or Non Squamous)	1
Stage 4 NSCLC	1
Malignant Neoplastic Disease	1
Advanced Malignancies	1
KRAS P.G12C	1
Metastatic Non-Squamous Non-Small Cell Lung Cancer	1
Adult Solid Tumor	1
Advanced Hepatocellular Carcinoma	1
Metastatic Hepatocellular Carcinoma	1
Unresectable or Metastatic Melanoma or Advanced Solid Tumors	1
Uveal Melanoma	1
P53 Mutation	1
Oncology	1
Squamous NSCLC	1
Non-squamous NSCLC	1
ALK Gene Mutation	1
Pancreas Cancer	1
Antibody	1
Disitamab Vedotin	1
Lenvatinib	1
Immune Checkpoint Inhibitors	1
Advanced Malignant Tumors	1
Advanced Non-small Cell Lung Cancer	1
Immune Checkpoint Inhibitor	1
Inoperable Locally Advanced HER2-Negative Breast Cancer	1
Metastatic HER2-Negative Breast Cancer	1
Non Small Cell Lung Cancer Metastatic	1
Stage II to III (T1cN1-2 or T2-4N0-2) TNBC Breast Cancer	1
Probiotics	1
Malignant Ascites	1
Rectum Cancer	1
Stomach Cancer	1
Stomach Cancer Recurrent	1
Stomach Cancer, Adenocarcinoma	1
Inoperable Disease	1
Advanced Malignant Solid Tumors	1
Oral Cancer	1
PD-1	1
Locally Advanced Rectal Cancer	1
Advanced Biliary Tract Cancer	1
Thyroid Neoplasms	1
Brain Metastases	1
Brain Cancer	1
Glioma	1
Intrahepatic Cholangiocarcinoma (Icc)	1
Gastric Carcinoma	1
Efficacy, Team	1
Adverse Event	1
Sarcoma	1
Leukaemia	1
Breast Cancer (Locally Advanced or Metastatic)	1
Stage IIIB(N2) Non-small Cell Lung Cancer	1
Stage IIA Non-small Cell Lung Cancer	1
Stage IIB Non-small Cell Lung Cancer	1
Stage IIIA Non-small Cell Lung Cancer	1
Tumor Thrombosis	1
Renal Cancer	1
HCC - Hepatocellular Carcinoma	1
HER2-negative Breast Cancer	1
Solid Cancer	1
Lymphoma, Extranodal NK-T-Cell	1
Lung Cancer Recurrent	1
Breast Carcinoma	1
Breast Cancer Metastatic	1
Breast Cancer Triple Negative	1
Endometrial Carcinoma (EC)	1
Squamous Head and Neck Carcinoma	1
Advanced or Metastatic NSCLC	1
Non-small Cell Lung Cancer Stage IV	1
Mucosal Melanoma	1
Neoadjuvant Treatment	1
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer	1
Head and Neck Squamous Cell Carcinomas	1

By country register

Register	Trials	Recruiting
Clinical trials in USA	331	185
Clinical trials in China	180	111
Clinical trials in UK	159	79
Clinical trials in Ireland	35	18
Clinical trials in India	31	23

A trial with sites in more than one country appears in each of those registers.

Related compounds

Questions about Pembrolizumab trials

How many clinical trials are testing Pembrolizumab?

409 current trials in our USA, China, UK, Ireland and India registers name Pembrolizumab (also registered as MK-3475) as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.

Are Pembrolizumab trials recruiting patients?

Yes. 232 of the 409 trials are recruiting: 185 with sites in USA, 111 with sites in China, 79 with sites in UK, 18 with sites in Ireland and 23 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Pembrolizumab clinical trials?

Merck Sharp & Dohme LLC (68), AstraZeneca (17), Eli Lilly and Company (11) and Astellas Pharma Global Development, Inc (11), among 187 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Is Pembrolizumab licensed in Ireland?

Yes. The HPRA medicines list includes 3 single-substance products containing Pembrolizumab, for example KEYTRUDA 25 mg/mL concentrate for solution for infusion (Merck Sharp & Dohme BV,). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Pembrolizumab shortage?

Not in the lists we track: Pembrolizumab has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Pembrolizumab works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Pembrolizumab works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Pembrolizumab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Pembrolizumab clinical trials